ME Therapeutics Holdings Inc.
METXF
$2.95
$0.000.09%
OTC PK
| 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.82% | -17.34% | -25.21% | -55.73% | 83.97% |
| Depreciation & Amortization | 44.76% | 150.00% | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 69.81% | 21.82% | 23.31% | -34.93% | 32.50% |
| Operating Income | -69.81% | -21.82% | -23.31% | 34.93% | -32.50% |
| Income Before Tax | -51.83% | -15.88% | -8.25% | 30.93% | -30.81% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -51.83% | -15.88% | -8.25% | 30.93% | -30.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -51.83% | -15.88% | -8.25% | 30.93% | -30.81% |
| EBIT | -69.81% | -21.82% | -23.31% | 34.93% | -32.50% |
| EBITDA | -80.67% | -22.04% | -19.57% | 37.01% | -19.26% |
| EPS Basic | -36.54% | 2.30% | 7.78% | 41.38% | -15.56% |
| Normalized Basic EPS | -33.33% | 1.85% | 8.77% | 41.76% | -17.86% |
| EPS Diluted | -4.29% | 2.30% | 7.78% | 42.18% | 5.41% |
| Normalized Diluted EPS | -33.33% | 1.85% | 8.77% | 41.76% | -17.86% |
| Average Basic Shares Outstanding | 11.98% | 18.27% | 17.52% | 17.94% | 13.76% |
| Average Diluted Shares Outstanding | 11.98% | 18.27% | 17.52% | 17.94% | 13.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |